

Antonio Di Biagio

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7868556/antonio-di-biagio-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

336
papers

5,164
citations

30
h-index

59
g-index

373
ext. papers

6,802
ext. citations

5
avg, IF

5.1
L-index

#	Paper	IF	Citations
336	Genetic mechanisms of critical illness in COVID-19. <i>Nature</i> , 2021 , 591, 92-98	50.4	451
335	Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. <i>Lancet, The</i> , 2019 , 393, 2428-2438	40	363
334	Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. <i>Lancet, The</i> , 2019 , 393, 1418-1427	40	175
333	CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. <i>Lancet HIV,the</i> , 2015 , 2, e98-106	7.8	172
332	The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring. <i>Aids</i> , 1999 , 13, 2083-9	3.5	137
331	ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population. <i>European Journal of Human Genetics</i> , 2020 , 28, 1602-1614	5.3	132
330	Bloodstream infections in critically ill patients with COVID-19. <i>European Journal of Clinical Investigation</i> , 2020 , 50, e13319	4.6	118
329	Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients. <i>Journal of Infectious Diseases</i> , 2015 , 211, 178-86	7	114
328	Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. <i>PLoS Medicine</i> , 2015 , 12, e1001809	11.6	107
327	Linezolid in the treatment of Gram-positive prosthetic joint infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2005 , 55, 387-90	5.1	88
326	Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. <i>Liver International</i> , 2017 , 37, 514-528	7.9	71
325	Cardiovascular risk and dyslipidemia among persons living with HIV: a review. <i>BMC Infectious Diseases</i> , 2017 , 17, 551	4	71
324	Tocilizumab and steroid treatment in patients with COVID-19 pneumonia. <i>PLoS ONE</i> , 2020 , 15, e0237831	3.7	62
323	Natural killer cells in HIV controller patients express an activated effector phenotype and do not up-regulate NKp44 on IL-2 stimulation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 11970-5	11.5	59
322	Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 1163-1171	5.1	56
321	Weight Gain: A Possible Side Effect of All Antiretrovirals. <i>Open Forum Infectious Diseases</i> , 2017 , 4, ofx239	1	55
320	Prevalence, awareness, treatment, and control rate of hypertension in HIV-infected patients: the HIV-HY study. <i>American Journal of Hypertension</i> , 2014 , 27, 222-8	2.3	53

319	Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings from a nested case-control study. <i>ELife</i> , 2021 , 10,	8.9	51
318	Clinical characteristics, management and in-hospital mortality of patients with coronavirus disease 2019 in Genoa, Italy. <i>Clinical Microbiology and Infection</i> , 2020 , 26, 1537-1544	9.5	50
317	Linezolid treatment of prosthetic hip Infections due to methicillin-resistant Staphylococcus aureus (MRSA). <i>Journal of Infection</i> , 2001 , 43, 148-9	18.9	46
316	Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 1886-96	5.1	39
315	Efficacy of ertapenem in the treatment of early ventilator-associated pneumonia caused by extended-spectrum beta-lactamase-producing organisms in an intensive care unit. <i>Journal of Antimicrobial Chemotherapy</i> , 2007 , 60, 433-5	5.1	39
314	Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort. <i>PLoS ONE</i> , 2016 , 11, e0164753	3.7	35
313	Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. <i>New Microbiologica</i> , 2010 , 33, 195-206 ¹	1.1	35
312	Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study. <i>Open Forum Infectious Diseases</i> , 2018 , 5, ofy113	1	34
311	The effect of formulary restriction in the use of antibiotics in an Italian hospital. <i>European Journal of Clinical Pharmacology</i> , 2001 , 57, 529-34	2.8	34
310	Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016 , 71, 263-71	3.1	33
309	Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trial. <i>PLoS ONE</i> , 2013 , 8, e80157	3.7	31
308	Determinants of Virologic and Immunologic Outcomes in Chronically HIV-Infected Subjects Undergoing Repeated Treatment Interruptions. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007 , 46, 39-47	3.1	31
307	Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy. <i>Scientific Reports</i> , 2018 , 8, 8988	4.9	30
306	The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen. <i>Aids</i> , 2020 , 34, 877-881	3.5	29
305	Bone quality in perinatally HIV-infected children: role of age, sex, growth, HIV infection, and antiretroviral therapy. <i>AIDS Research and Human Retroviruses</i> , 2005 , 21, 927-32	1.6	29
304	Novel antiretroviral drugs and renal function monitoring of HIV patients. <i>AIDS Reviews</i> , 2014 , 16, 144-51	1.5	29
303	Impact of a mixed educational and semi-restrictive antimicrobial stewardship project in a large teaching hospital in Northern Italy. <i>Infection</i> , 2017 , 45, 849-856	5.8	28
302	Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir. <i>Aids</i> , 2009 , 23, 534-8	3.5	28

301	Incidence and Prognosis of Ventilator-Associated Pneumonia in Critically Ill Patients with COVID-19: A Multicenter Study. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	28
300	Dolutegravir Plus Rilpivirine as a Switch Option in cART-Experienced Patients: 96-Week Data. <i>Annals of Pharmacotherapy</i> , 2018 , 52, 740-746	2.9	27
299	Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort. <i>Clinical Microbiology and Infection</i> , 2016 , 22, 288.e1-8	9.5	27
298	Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine. <i>Aids</i> , 2010 , 24, 1013-8	3.5	27
297	Successfully treated HIV-infected patients have differential expression of NK cell receptors (NKp46 and NKp30) according to AIDS status at presentation. <i>Immunology Letters</i> , 2013 , 152, 16-24	4.1	26
296	Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals. <i>International Journal of Antimicrobial Agents</i> , 2005 , 26, 88-91	14.3	26
295	Impact of an antimicrobial formulary and restriction policy in the largest hospital in Italy. <i>International Journal of Antimicrobial Agents</i> , 2000 , 16, 295-9	14.3	26
294	Kidney disease and all-cause mortality in patients with COVID-19 hospitalized in Genoa, Northern Italy. <i>Journal of Nephrology</i> , 2021 , 34, 173-183	4.8	26
293	Control of the HIV-1 DNA Reservoir Is Associated and with NKp46/NKp30 (CD335 CD337) Inducibility and Interferon Gamma Production by Transcriptionally Unique NK Cells. <i>Journal of Virology</i> , 2017 , 91,	6.6	25
292	Bloodstream infections in HIV-infected patients. <i>Virulence</i> , 2016 , 7, 320-8	4.7	25
291	Raltegravir central nervous system tolerability in clinical practice: results from a multicenter observational study. <i>Aids</i> , 2012 , 26, 2412-5	3.5	25
290	Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males. <i>EBioMedicine</i> , 2021 , 65, 103246	8.8	25
289	Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort. <i>Journal of the International AIDS Society</i> , 2019 , 22, e25227	5.4	24
288	Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration. <i>Journal of Antimicrobial Chemotherapy</i> , 2006 , 57, 1168-71	5.1	24
287	Renal complications in HIV disease: between present and future. <i>AIDS Reviews</i> , 2012 , 14, 37-53	1.5	24
286	Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillance. <i>International Journal of Antimicrobial Agents</i> , 2015 , 45, 289-94	14.3	23
285	Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?. <i>Journal of Hepatology</i> , 2018 , 68, 597-600	13.4	23
284	Factors Associated With Weight Gain in People Treated With Dolutegravir. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa195	1	22

283	Trichosporon asahii infection treated with caspofungin combined with liposomal amphotericin B. <i>Journal of Antimicrobial Chemotherapy</i> , 2004 , 54, 575-7	5.1	22
282	Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016. <i>HIV Medicine</i> , 2018 , 19, 619-628	2.7	21
281	Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA). <i>BMC Infectious Diseases</i> , 2018 , 18, 357	4	21
280	Effects of the change from Stavudine to tenofovir in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy: studies on mitochondrial toxicity and thymic function. <i>Pediatric Infectious Disease Journal</i> , 2008 , 27, 17-21	3.4	21
279	Successful treatment of methicillin-resistant Staphylococcus aureus endocarditis with linezolid. <i>International Journal of Antimicrobial Agents</i> , 2004 , 24, 83-4	14.3	21
278	Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research. <i>European Journal of Human Genetics</i> , 2021 , 29, 745-759	5.3	20
277	Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 1955-1964	5.1	20
276	Behind the screens: Clinical decision support methodologies – A review. <i>Health Policy and Technology</i> , 2015 , 4, 29-38	4.8	19
275	Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results. <i>Aids</i> , 2014 , 28, 2269-79	3.5	19
274	Cost-effectiveness analysis of initial HIV treatment under Italian guidelines. <i>ClinicoEconomics and Outcomes Research</i> , 2011 , 3, 197-205	1.7	19
273	Fatal lactic acidosis and mimicking Guillain-Barré syndrome in an adolescent with human immunodeficiency virus infection. <i>Pediatric Infectious Disease Journal</i> , 2003 , 22, 668-670	3.4	19
272	Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group. <i>New Microbiologica</i> , 2012 , 35, 17-25	1.1	19
271	Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 177-182	5.1	18
270	Extensive activation, tissue trafficking, turnover and functional impairment of NK cells in COVID-19 patients at disease onset associates with subsequent disease severity. <i>PLoS Pathogens</i> , 2021 , 17, e1009448	7.6	18
269	Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2016. <i>New Microbiologica</i> , 2017 , 40, 86-98	1.1	18
268	Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 1363-1367	5.1	17
267	Osteonecrosis in human immunodeficiency virus (HIV)-infected patients: a multicentric case-control study. <i>Journal of Bone and Mineral Metabolism</i> , 2011 , 29, 383-8	2.9	17
266	Candida infections in the intensive care unit: epidemiology, risk factors and therapeutic strategies. <i>Expert Review of Anti-Infective Therapy</i> , 2006 , 4, 875-85	5.5	17

265	Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study. <i>BMC Medicine</i> , 2018 , 16, 79	11.4	16
264	Emergence of bone-marrow-resident CD34(+)DNAM-1(bright)CXCR4(+)-committed lymphoid precursors during chronic infection and inflammation. <i>Nature Communications</i> , 2015 , 6, 8109	17.4	16
263	The Ligurian human immunodeficiency virus clinical network: a web tool to manage patients with human immunodeficiency virus in primary care and multicenter clinical trials. <i>Medicine 2 0</i> , 2013 , 2, e5		16
262	Factors associated with hospital admission for COVID-19 in HIV patients. <i>Aids</i> , 2020 , 34, 1983-1985	3.5	16
261	The Longest Persistence of Viable SARS-CoV-2 With Recurrence of Viremia and Relapsing Symptomatic COVID-19 in an Immunocompromised Patient-A Case Study. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab217	1	16
260	HIV-1 A1 Subtype Epidemic in Italy Originated from Africa and Eastern Europe and Shows a High Frequency of Transmission Chains Involving Intravenous Drug Users. <i>PLoS ONE</i> , 2016 , 11, e0146097	3.7	16
259	Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. <i>Open Forum Infectious Diseases</i> , 2016 , 3, ofw009	1	16
258	Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project. <i>PLoS ONE</i> , 2017 , 12, e0179254	3.7	15
257	Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 735-41	5.1	15
256	Major differences in organization and availability of health care and medicines for HIV/TB coinfecting patients across Europe. <i>HIV Medicine</i> , 2015 , 16, 544-52	2.7	15
255	The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy. <i>Journal of Medical Virology</i> , 2014 , 86, 1648-55	19.7	15
254	Increasing prevalence of genitourinary schistosomiasis in Europe in the Migrant Era: Neglected no more?. <i>PLoS Neglected Tropical Diseases</i> , 2017 , 11, e0005237	4.8	15
253	Influence of indinavir and ritonavir on warfarin anticoagulant activity. <i>Aids</i> , 1998 , 12, 825-6	3.5	15
252	Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 2570-2584	15.1	14
251	From Liguria HIV Web to Liguria Infectious Diseases Network: How a Digital Platform Improved Doctors' Work and Patients' Care. <i>AIDS Research and Human Retroviruses</i> , 2018 , 34, 239-240	1.6	14
250	CD8 ⁺ CD28 ⁺ CD127 ⁺ CD39 ⁺ regulatory T-cell expansion: A new possible pathogenic mechanism for HIV infection?. <i>Journal of Allergy and Clinical Immunology</i> , 2018 , 141, 2220-2233.e4	11.5	14
249	The second generation of HIV-1 vertically exposed infants: a case series from the Italian Register for paediatric HIV infection. <i>BMC Infectious Diseases</i> , 2014 , 14, 277	4	14
248	Safety and durability in a cohort of HIV-1 positive patients treated with once and twice daily darunavir-based therapy (SCOLTA Project). <i>Biomedicine and Pharmacotherapy</i> , 2013 , 67, 293-8	7.5	14

247	Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 200-5	5.1	14
246	<i>Streptococcus pyogenes</i> erythromycin resistance in Italy. <i>Emerging Infectious Diseases</i> , 1999 , 5, 302-3	10.2	14
245	Bedaquiline: A New Hope for Shorter and Better Anti-Tuberculosis Regimens. <i>Recent Patents on Anti-infective Drug Discovery</i> , 2018 , 13, 3-11	1.6	14
244	Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy. <i>BMC Public Health</i> , 2018 , 18, 870	4.1	13
243	Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia. <i>PLoS ONE</i> , 2019 , 14, e0223181	3.7	13
242	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 427-434	18.8	13
241	Transitioning HIV-infected children and adolescents into adult care: an Italian real-life experience. <i>Journal of the Association of Nurses in AIDS Care</i> , 2015 , 26, 652-9	1.6	13
240	Predictive factors of hyperlipidemia in HIV-infected subjects receiving lopinavir/ritonavir. <i>AIDS Research and Human Retroviruses</i> , 2006 , 22, 132-8	1.6	13
239	Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (. <i>HIV Medicine</i> , 2004 , 5, 1-10	2.7	13
238	Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 3295-3304	5.1	12
237	Clusterization of co-morbidities and multi-morbidities among persons living with HIV: a cross-sectional study. <i>BMC Infectious Diseases</i> , 2019 , 19, 555	4	12
236	HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 739-50	5.1	12
235	Patient-reported outcomes and low-level residual HIV-RNA in adolescents perinatally infected with HIV-1 after switching to one-pill fixed-dose regimen. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2012 , 24, 54-8	2.2	12
234	96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience. <i>PLoS ONE</i> , 2012 , 7, e39222	3.7	12
233	Risk factors for chronic kidney disease among human immunodeficiency virus-infected patients: A European case control study. <i>Clinical Nephrology</i> , 2011 , 75, 518-23	2.1	12
232	Treatment of hepatitis C virus genotype 4 in the DAA era. <i>Virology Journal</i> , 2018 , 15, 180	6.1	12
231	Determinants of patient and health care services delays for tuberculosis diagnosis in Italy: a cross-sectional observational study. <i>BMC Infectious Diseases</i> , 2018 , 18, 690	4	12
230	Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens. <i>PLoS ONE</i> , 2017 , 12, e0177352	3.7	11

229	Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project. <i>Infection and Drug Resistance</i> , 2018 , 11, 615-623	4.2	11
228	Pegylated interferon β plus ribavirin for the treatment of chronic hepatitis C: a multicentre independent study supported by the Italian Drug Agency. <i>Digestive and Liver Disease</i> , 2014 , 46, 826-32	3.3	11
227	Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E Study. <i>International Journal of Antimicrobial Agents</i> , 2014 , 43, 189-94	14.3	11
226	Use of raltegravir in a late presenter HIV-1 woman in advanced gestational age: case report and literature review. <i>Journal of Chemotherapy</i> , 2013 , 25, 181-3	2.3	11
225	Therapeutical aspects and outcome of HIV/HCV coinfecting patients treated with pegylated interferon plus ribavirin in an Italian cohort. <i>Infection</i> , 2008 , 36, 358-61	5.8	11
224	Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Name for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004-2014. <i>HIV Medicine</i> , 2019 , 20, 99-109	2.7	11
223	Seroprevalence and vaccination coverage of vaccine-preventable diseases in perinatally HIV-1-infected patients. <i>Human Vaccines and Immunotherapeutics</i> , 2015 , 11, 263-9	4.4	10
222	Role of linezolid in the treatment of orthopedic infections. <i>Expert Review of Anti-Infective Therapy</i> , 2005 , 3, 343-52	5.5	10
221	Inflammation markers correlate with common carotid intima-media thickness in patients perinatally infected with human immunodeficiency virus 1. <i>Journal of Ultrasound in Medicine</i> , 2013 , 32, 763-8	2.9	10
220	Characterization of T lymphocytes in severe COVID-19 patients. <i>Journal of Medical Virology</i> , 2021 , 93, 5608-5613	19.7	10
219	First-line antiretroviral therapy with efavirenz plus tenofovir disoproxil fumarate/emtricitabine or rilpivirine plus tenofovir disoproxil fumarate/emtricitabine: a durability comparison. <i>HIV Medicine</i> , 2018 , 19, 475	2.7	10
218	Gram-positive bacterial resistance. A challenge for the next millennium. <i>Panminerva Medica</i> , 2002 , 44, 179-84	2	10
217	Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA $\geq 10^5$ cp/mL. <i>Infection</i> , 2017 , 45, 521-528	5.8	9
216	Statins and aspirin in the prevention of cardiovascular disease among HIV-positive patients between controversies and unmet needs: review of the literature and suggestions for a friendly use. <i>AIDS Research and Therapy</i> , 2019 , 16, 11	3	9
215	Darunavir-based dual therapy of treatment-experienced HIV-infected patients: analysis from a national multicenter database. <i>Infection</i> , 2015 , 43, 339-43	5.8	9
214	Clofazimine: an old drug for never-ending diseases. <i>Future Microbiology</i> , 2020 , 15, 557-566	2.9	9
213	Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 2663-9	5.1	9
212	Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA). <i>Journal of Clinical Virology</i> , 2018 , 105, 112-117	14.5	9

211	Gender differences in HIV infection: is there a problem? Analysis from the SCOLTA cohorts. <i>Biomedicine and Pharmacotherapy</i> , 2014 , 68, 385-90	7.5	9
210	Liver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis C coinfection: data from the ICONA foundation cohort. <i>HIV Clinical Trials</i> , 2014 , 15, 151-60		9
209	Xpert HIV-1 Viral Load Assay and VERSANT HIV-1 RNA 1.5 Assay: A Performance Comparison. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017 , 74, e86-e88	3.1	9
208	The problem of renal function monitoring in patients treated with the novel antiretroviral drugs. <i>HIV Clinical Trials</i> , 2014 , 15, 87-91		9
207	Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database. <i>Clinical Microbiology and Infection</i> , 2013 , 19, 936-42	9.5	9
206	Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient. <i>Journal of Antimicrobial Chemotherapy</i> , 2009 , 64, 874-5	5.1	9
205	Whole body bone scintigraphy in tenofovir-related osteomalacia: a case report. <i>Journal of Medical Case Reports</i> , 2009 , 3, 8136	1.2	9
204	Successful rescue therapy with Raltegravir (MK-0518) and Etravirine (TMC125) in an hiv-infected patient failing all four classes of antiretroviral drugs. <i>AIDS Patient Care and STDs</i> , 2008 , 22, 355-7	5.8	9
203	Penetration of didanosine in semen of HIV-1-infected men. <i>Journal of Antimicrobial Chemotherapy</i> , 2006 , 57, 1244-7	5.1	9
202	Pharmacokinetics of rifabutin in HIV-infected patients with or without wasting syndrome. <i>British Journal of Clinical Pharmacology</i> , 1999 , 48, 704-11	3.8	9
201	Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial. <i>PLoS ONE</i> , 2017 , 12, e0187393	3.7	9
200	HIV and tuberculosis: The paradox of dual illnesses and the challenges of their fighting in the history. <i>Tuberculosis</i> , 2020 , 122, 101921	2.6	9
199	Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort. <i>HIV Medicine</i> , 2019 , 20, 137-146	2.7	9
198	Delay in schistosomiasis diagnosis and treatment: a multicenter cohort study in Italy. <i>Journal of Travel Medicine</i> , 2020 , 27,	12.9	9
197	Prevalence and Clinical Significance of Persistent Viral Shedding in Hospitalized Adult Patients with SARS-CoV-2 Infection: A Prospective Observational Study. <i>Infectious Diseases and Therapy</i> , 2021 , 10, 387-398	6.3	9
196	Evidence-based renewal of the Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. <i>New Microbiologica</i> , 2018 , 41, 247-255	1.1	9
195	Hepatitis B Virus Vaccination in HIV: Immunogenicity and Persistence of Seroprotection up to 7 Years Following a Primary Immunization Course. <i>AIDS Research and Human Retroviruses</i> , 2018 , 34, 922-928	1.6	8
194	HIV and accelerated atheroprogession: role of antiretroviral therapy. <i>Current Pharmaceutical Biotechnology</i> , 2012 , 13, 88-96	2.6	8

193	The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile. <i>Drug Design, Development and Therapy</i> , 2020 , 14, 5515-5520	4.4	8
192	Tocilizumab and steroid treatment in patients with COVID-19 pneumonia		8
191	How relevant is the HIV low level viremia and how is its management changing in the era of modern ART? A large cohort analysis. <i>Journal of Clinical Virology</i> , 2020 , 123, 104255	14.5	8
190	Bronchoalveolar lavage fluid characteristics and outcomes of invasively mechanically ventilated patients with COVID-19 pneumonia in Genoa, Italy. <i>BMC Infectious Diseases</i> , 2021 , 21, 353	4	8
189	Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data. <i>Pharmacoeconomics</i> , 2019 , 37, 255-266	4.4	8
188	The longest persistence of viable SARS-CoV-2 with recurrence of viremia and relapsing symptomatic COVID-19 in an immunocompromised patient: a case study		8
187	Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C. <i>Liver International</i> , 2021 , 41, 1802-1814	7.9	8
186	Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. <i>Clinical Microbiology and Infection</i> , 2017 , 23, 267.e1-267.e4	9.5	7
185	Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB:HIV study. <i>Journal of Infection</i> , 2018 , 76, 44-54	18.9	7
184	Switch from unboosted protease inhibitor to a single-tablet regimen containing rilpivirine improves cholesterol and triglycerides. <i>International Journal of Antimicrobial Agents</i> , 2016 , 48, 551-554	14.3	7
183	The Italian registry of pulmonary non-tuberculous mycobacteria - IRENE: the study protocol. <i>Multidisciplinary Respiratory Medicine</i> , 2018 , 13, 33	3	7
182	Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group. <i>Infection</i> , 2014 , 42, 61-71	5.8	7
181	Efficacy and safety of darunavir/ritonavir plus etravirine dual regimen in antiretroviral therapy-experienced patients: a multicenter clinical experience. <i>HIV Clinical Trials</i> , 2014 , 15, 140-50		7
180	Budget impact analysis of sofosbuvir-based regimens for the treatment of HIV/HCV-coinfected patients in northern Italy: a multicenter regional simulation. <i>ClinicoEconomics and Outcomes Research</i> , 2016 , 8, 15-21	1.7	7
179	Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus. <i>PLoS ONE</i> , 2015 , 10, e0140877	3.7	7
178	Increased CD38 expression on T lymphocytes as a marker of HIV dissemination into the central nervous system. <i>HIV Clinical Trials</i> , 2015 , 16, 190-6		7
177	Raltegravir-based therapy in a cohort of HIV/HCV co-infected individuals. <i>Biomedicine and Pharmacotherapy</i> , 2015 , 69, 233-6	7.5	7
176	Genotypic determination of HIV tropism in a cohort of patients perinatally infected with HIV-1 and exposed to antiretroviral therapy. <i>HIV Clinical Trials</i> , 2014 , 15, 45-50		7

175	TB meningitis in HIV-positive patients in Europe and Argentina: clinical outcome and factors associated with mortality. <i>BioMed Research International</i> , 2013 , 2013, 373601	3	7
174	Rs12979860 and rs8099917 single nucleotide polymorphisms of interleukin-28B gene: simultaneous genotyping in caucasian patients infected with hepatitis C virus. <i>Journal of Preventive Medicine and Hygiene</i> , 2013 , 54, 83-6	1.4	7
173	Switching from efavirenz to rilpivirine improves sleep quality and self-perceived cognition but has no impact on neurocognitive performances. <i>Aids</i> , 2020 , 34, 53-61	3.5	7
172	Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program. <i>Clinical Infectious Diseases</i> , 2017 , 64, 680-683	11.6	7
171	The Management of Geriatric and Frail HIV Patients. A 2017 Update from the Italian Guidelines for the Use of Antiretroviral Agents and the Diagnostic Clinical Management of HIV-1 Infected Persons. <i>Journal of Frailty & Aging, the</i> , 2019 , 8, 10-16	2.6	7
170	Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 3460-3470	5.1	7
169	Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis. <i>Infection</i> , 2018 , 46, 607-615	5.8	7
168	A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4. <i>PLoS ONE</i> , 2019 , 14, e0222650	3.7	6
167	Missed opportunities to prevent mother-to-child transmission of HIV in Italy. <i>HIV Medicine</i> , 2019 , 20, 330-336	2.7	6
166	Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. <i>Journal of Viral Hepatitis</i> , 2015 , 22, 469-80	3.4	6
165	Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients. <i>Clinical Microbiology and Infection</i> , 2019 , 25, 1443-1446	9.5	6
164	Efficacy, safety, and patient acceptability of elvitegravir/cobicistat/emtricitabine/tenofovir in the treatment of HIV/AIDS. <i>Patient Preference and Adherence</i> , 2015 , 9, 1213-8	2.4	6
163	Decreasing cardiovascular risk in HIV infection between 2005 and 2011. <i>Aids</i> , 2014 , 28, 609-12	3.5	6
162	Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 3085-94	5.1	6
161	Case report: management and HBV sequencing in a patient co-infected with HBV and HIV failing tenofovir. <i>Journal of Medical Virology</i> , 2012 , 84, 1340-3	19.7	6
160	Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009. <i>Clinical Microbiology and Infection</i> , 2011 , 17, 1352-5	9.5	6
159	A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimen. <i>BMC Medical Informatics and Decision Making</i> , 2011 , 11, 40	3.6	6
158	Prevalence of mutations and determinants of genotypic resistance to etravirine (TMC125) in a large Italian resistance database (ARCA). <i>HIV Medicine</i> , 2010 , 11, 530-4	2.7	6

157	The use of nucleoside reverse transcriptase inhibitors sparing regimens in treatment-experienced HIV-1 infected patients. <i>Current HIV Research</i> , 2013 , 11, 179-86	1.3	6
156	How has the cost of antiretroviral therapy changed over the years? A database analysis in Italy. <i>BMC Health Services Research</i> , 2018 , 18, 691	2.9	6
155	State of the Art of Dual Therapy in 2015. <i>AIDS Reviews</i> , 2015 , 17, 127-34	1.5	6
154	Quality of life in an Italian cohort of people living with HIV in the era of combined antiretroviral therapy (Evidence from I.A.N.U.A. study-investigation on antiretroviral therapy). <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2017 , 29, 1373-1377	2.2	5
153	Co-administration of tenofovir plus protease inhibitor based antiretroviral therapy during sofosbuvir/ledipasvir treatment for HCV infection: Much Ado About Nothing?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2017 , 41, e76-e79	2.4	5
152	Pregnancy and neonatal outcomes among a cohort of HIV-infected women in a large Italian teaching hospital: a 30-year retrospective study. <i>Epidemiology and Infection</i> , 2017 , 145, 1658-1669	4.3	5
151	Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts 5 log10 copies/mL. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 2732-2741	5.1	5
150	Inpatient admissions of patients living with HIV in two European centres (UK and Italy); comparisons and contrasts. <i>Journal of Infection</i> , 2015 , 70, 690-4	18.9	5
149	PrEP in Italy: The time may be ripe but who's paying the bill? A nationwide survey on physicians' attitudes towards using antiretrovirals to prevent HIV infection. <i>PLoS ONE</i> , 2017 , 12, e0181433	3.7	5
148	Predictors of retention in care in HIV-infected patients in a large hospital cohort in Italy. <i>Epidemiology and Infection</i> , 2018 , 146, 606-611	4.3	5
147	Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 1637-42	5.1	5
146	Evaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of HIV-Infected People Seen for Care in Italy. <i>PLoS ONE</i> , 2015 , 10, e0124252	3.7	5
145	Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome. <i>Digestive and Liver Disease</i> , 2015 , 47, 157-63	3.3	5
144	Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19825-4	5.4	5
143	Innate immunity cell activation in virologically suppressed HIV-infected maraviroc-treated patients. <i>Aids</i> , 2014 , 28, 1071-4	3.5	5
142	Safety and efficacy of pegylated interferon and ribavirin in adolescents with human immunodeficiency virus and hepatitis C virus acquired perinatally. <i>Journal of Medical Virology</i> , 2010 , 82, 1110-4	19.7	5
141	The organization of infection control in Italy. <i>Journal of Hospital Infection</i> , 2001 , 48, 83-5	6.9	5
140	Trend of estimated glomerular filtration rate during ombitasvir/paritaprevir/ritonavir plus dasabuvir + ribavirin in HIV/HCV co-infected patients. <i>PLoS ONE</i> , 2018 , 13, e0192627	3.7	5

139	Enhanced Immunological Recovery With Early Start of Antiretroviral Therapy During Acute or Early HIV Infection-Results of Italian Network of ACuTe HIV Infection (INACTION) Retrospective Study. <i>Pathogens and Immunity</i> , 2020 , 5, 8-33	4.9	5
138	Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data From the PRESTIGIO Registry. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa456	1	5
137	Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy. <i>Viruses</i> , 2020 , 12,	6.2	5
136	Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials. <i>AIDS Research and Human Retroviruses</i> , 2020 , 36, 48-57	1.6	5
135	HIV-1 co-receptor tropism and liver fibrosis in HIV-infected patients. <i>PLoS ONE</i> , 2018 , 13, e0190302	3.7	4
134	Durability of Second Antiretroviral Regimens in the Italian Cohort Naive Antiretrovirals Foundation Study and Factors Associated with Discontinuation. <i>AIDS Patient Care and STDs</i> , 2017 , 31, 487-494	5.8	4
133	Vaginal HIV-1 shedding among HIV-1 infected women in the current era of combined antiretroviral therapy: A cross sectional study. <i>Virulence</i> , 2017 , 8, 101-108	4.7	4
132	Benign lymphoepithelial parotid lesions in vertically HIV-infected patients. <i>AIDS Patient Care and STDs</i> , 2006 , 20, 536-41	5.8	4
131	New antibiotics for treatment of serious infections due to antibiotic-resistant Gram-positive cocci. <i>Reviews in Medical Microbiology</i> , 2004 , 15, 109-117	1.1	4
130	Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice. <i>PLoS ONE</i> , 2016 , 11, e0160761	3.7	4
129	Addition of Maraviroc Versus Placebo to Standard Antiretroviral Therapy for Initial Treatment of Advanced HIV Infection: A Randomized Trial. <i>Annals of Internal Medicine</i> , 2020 , 172, 297-305	8	4
128	Reply to: "Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19". <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa321	1	4
127	Smoking Habits in Human Immunodeficiency Virus-Infected People from Italy: A Cross-Sectional Analysis of the STOPSHIV Cohort. <i>AIDS Research and Human Retroviruses</i> , 2020 , 36, 19-26	1.6	4
126	The Impact of the SARS-CoV-2 Outbreak on the Psychological Flexibility and Behaviour of Cancelling Medical Appointments of Italian Patients with Pre-Existing Medical Condition: The "ImpACT-COVID-19 for Patients" Multi-Centre Observational Study. <i>International Journal of Environmental Research and Public Health</i> , 2021 , 18,	4.6	4
125	Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study. <i>AIDS Patient Care and STDs</i> , 2021 , 35, 342-353	5.8	4
124	Does Syphilis Increase the Risk of HIV-RNA Elevation >200 Copies/mL in HIV-Positive Patients Under Effective Antiretroviral Treatment? Data From the ICONA Cohort. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021 , 88, 132-137	3.1	4
123	Fatal lactic acidosis and mimicking Guillain-Barré syndrome in an adolescent with human immunodeficiency virus infection. <i>Pediatric Infectious Disease Journal</i> , 2003 , 22, 668-70	3.4	4
122	Use of statins and aspirin to prevent cardiovascular disease among HIV-positive patients. A survey among Italian HIV physicians. <i>New Microbiologica</i> , 2017 , 40, 139-142	1.1	4

121	Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients.. <i>Genes and Immunity</i> , 2021 ,	4.4	4
120	Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection?. <i>BMC Public Health</i> , 2019 , 19, 1291	4.1	3
119	Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA). <i>AIDS Research and Therapy</i> , 2019 , 16, 21	3	3
118	Is the rate of virological failure to cART continuing to decline in recent calendar years?. <i>Journal of Clinical Virology</i> , 2019 , 116, 23-28	14.5	3
117	Bloodstream infections in patients living with HIV in the modern cART era. <i>Scientific Reports</i> , 2019 , 9, 5418	4.9	3
116	Successful antiretroviral therapy by using unusual antiretroviral combinations in heavily pre-treated patients: two case reports. <i>International Journal of STD and AIDS</i> , 2015 , 26, 831-4	1.4	3
115	Switching to Integrase Inhibitors Unlinked to Weight Increase in Perinatally HIV-Infected Young Adults and Adolescents: A 10-Year Observational Study. <i>Microorganisms</i> , 2020 , 8,	4.9	3
114	Comment on: Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 3698-3699	5.1	3
113	Socioeconomic status and biomedical risk factors in migrants and native tuberculosis patients in Italy. <i>PLoS ONE</i> , 2017 , 12, e0189425	3.7	3
112	Dasabuvir and Ombitasvir/Paritaprevir/Ritonavir with or without Ribavirin in Patients with HIV-HCV Coinfection: Real Life Interim Analysis of an Italian Multicentre Compassionate Use Program. <i>Journal of Hepatology</i> , 2016 , 64, S763	13.4	3
111	Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated With Incident and Prevalent Type 2 Diabetes in Persons Living With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017 , 75, 465-471	3.1	3
110	Is it still worthwhile to perform quarterly cd4+ t lymphocyte cell counts on hiv-1 infected stable patients?. <i>BMC Infectious Diseases</i> , 2017 , 17, 127	4	3
109	Disseminated histoplasmosis with mucocutaneous immune reconstitution inflammatory syndrome in an HIV-infected patient. <i>AIDS Research and Human Retroviruses</i> , 2015 , 31, 274-5	1.6	3
108	Feasibility and reproducibility of HIV-1 genotype resistance test in very-low-level viremia. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 7620-1	5.9	3
107	Effects of hepatitis C virus infection on the pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected patients. <i>Journal of Infection and Chemotherapy</i> , 2012 , 18, 587-90	2.2	3
106	Lamivudine resistance mutations in European patients with hepatitis B and patients co-infected with HIV and hepatitis B. <i>Journal of Medical Virology</i> , 2011 , 83, 1905-8	19.7	3
105	Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone. <i>Infection</i> , 2007 , 35, 451-6	5.8	3
104	Infectious complications of cancer chemotherapy in HIV patients. <i>Current Infectious Disease Reports</i> , 2008 , 10, 149-56	3.9	3

103	Use of lopinavir/ritonavir in HIV-infected patients failing a first-line protease-inhibitor-containing HAART. <i>Journal of Antimicrobial Chemotherapy</i> , 2005 , 55, 1003-7	5.1	3
102	Use of antibiotics in an Italian children's hospital, 1993-1995; clinical and economic considerations. <i>International Journal of Antimicrobial Agents</i> , 2000 , 14, 33-7	14.3	3
101	Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity. <i>Human Genetics</i> , 2021 , 141, 147	6.3	3
100	Prevalence and prognostic value of cardiac troponin in elderly patients hospitalized for COVID-19. <i>Journal of Geriatric Cardiology</i> , 2021 , 18, 338-345	1.7	3
99	Novelties in evaluation and monitoring of HIV-1 infection: Is standard virological suppression enough for measuring antiretroviral treatment success?. <i>AIDS Reviews</i> , 2017 , 19,	1.5	3
98	Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?. <i>Clinical Infectious Diseases</i> , 2020 , 71, 2905-2916 ³	11.6	3
97	Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings. <i>Journal of Clinical Virology</i> , 2020 , 130, 104534	14.5	3
96	Higher Mortality and Intensive Care Unit Admissions in COVID-19 Patients with Liver Enzyme Elevations. <i>Microorganisms</i> , 2020 , 8,	4.9	3
95	Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients. <i>Journal of the International Association of Providers of AIDS Care</i> , 2019 , 18, 2325958218821657	1.7	3
94	Injectable Antiretroviral Drugs: Back to the Future. <i>Viruses</i> , 2021 , 13,	6.2	3
93	Real-World Analysis of Survival and Clinical Events in a Cohort of Italian Perinatally HIV-1 Infected Children From 2001 to 2018. <i>Frontiers in Pediatrics</i> , 2021 , 9, 665764	3.4	3
92	IANUA: a regional project for the determination of costs in HIV-infected patients. <i>Studies in Health Technology and Informatics</i> , 2015 , 210, 241-5	0.5	3
91	Role of Raltegravir in patients co-infected with HIV and HCV in the era of direct antiviral agents. <i>New Microbiologica</i> , 2017 , 40, 227-233	1.1	3
90	A Comprehensive Development Agenda on Tenofovir Alafenamide in Clinical Practice. <i>AIDS Reviews</i> , 2018 , 20, 75-82	1.5	2
89	Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2019 , 38, 1857-1865	5.3	2
88	Is it time to re-think the use of etravirine in patients with available genotypic resistance test?. <i>Infectious Diseases</i> , 2019 , 51, 452-455	3.1	2
87	Role of HCV-RNA decay and IP-10 levels after 48 hours of standard HCV therapy as predictors of rapid virological response. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015 , 39, 705-10	2.4	2
86	Predictors of incomplete viral response and virologic failure in patients with acute and early HIV infection. Results of Italian Network of ACuTe HIV InfectiON (INACTiON) cohort. <i>HIV Medicine</i> , 2020 , 21, 523-535	2.7	2

85	Time to change the single-centre approach to management of patients with tuberculosis: a novel network platform with automatic data import and data sharing. <i>ERJ Open Research</i> , 2018 , 4,	3.5	2
84	Immune activation, inflammation and HIV DNA after 96 weeks of ATV/r monotherapy: a MODAt substudy. <i>Antiviral Therapy</i> , 2018 , 23, 633-637	1.6	2
83	Effectiveness of first-generation HCV protease inhibitors: does HIV coinfection still play a role?. <i>European Journal of Gastroenterology and Hepatology</i> , 2016 , 28, 37-41	2.2	2
82	Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: data from the Icona Foundation cohort. <i>HIV Medicine</i> , 2015 , 16, 412-20	2.7	2
81	Decrease of renal function in HCV and HIV/HCV-infected patients with telaprevir-based therapy. <i>Aids</i> , 2015 , 29, 2061-2	3.5	2
80	Inflammation Markers Correlate With Common Carotid Intima-Media Thickness in Patients Perinatally Infected With Human Immunodeficiency Virus 1. <i>Journal of Ultrasound in Medicine</i> , 2013 , 32, 763-768	2.9	2
79	Different evidence of key amprenavir resistance mutations on the efficacy of darunavir. <i>Aids</i> , 2008 , 22, 437-8	3.5	2
78	Efficacy of the combination of levofloxacin plus ceftazidime in the treatment of hospital-acquired pneumonia in the intensive care unit. <i>International Journal of Antimicrobial Agents</i> , 2006 , 28, 582-5	14.3	2
77	Clinically stable treatment-experienced adults receiving tenofovir and didanosine. <i>HIV Clinical Trials</i> , 2006 , 7, 10-5		2
76	. <i>Pediatric Infectious Disease Journal</i> , 2003 , 22, 668-670	3.4	2
75	Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 681-689	5.1	2
74	Is It Feasible to Impact on Smoking Habits in HIV-Infected Patients? Mission Impossible From the STOPSHIV Project Cohort. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020 , 83, 496-503	3.1	2
73	High doses of hydroxychloroquine do not affect viral clearance in patients with SARS-CoV-2 infection. <i>European Journal of Clinical Investigation</i> , 2020 , 50, e13358	4.6	2
72	Is a step-down antiretroviral therapy necessary to fight severe acute respiratory syndrome coronavirus 2 in HIV-infected patients?. <i>Aids</i> , 2020 , 34, 1865-1867	3.5	2
71	The impact of DAA-mediated HCV eradication on CD4 and CD8 T lymphocyte trajectories in HIV/HCV coinfecting patients: Data from the ICONA Foundation Cohort. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 779-786	3.4	2
70	Chemotherapy Mass Campaigns and Migratory Flows: An Unexpected Connection. <i>Clinical Infectious Diseases</i> , 2016 , 62, 1323	11.6	2
69	Potential role of raltegravir-based therapy to induce rapid viral decay in highly viraemic HIV-infected neonates. <i>Journal of Chemotherapy</i> , 2016 , 28, 337-40	2.3	2
68	The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019 , 81, e17-e21	3.1	2

67	HCV elimination plan leads to significant benefits in managing liver-related diseases and hospital interventions: a regional simulation. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019 , 19, 189-193	2.2	2
66	Healthcare delivery for HIV-positive people with tuberculosis in Europe. <i>HIV Medicine</i> , 2021 , 22, 283-293	2.7	2
65	Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021 , 86, 119-127	3.1	2
64	Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients. <i>HIV Clinical Trials</i> , 2018 , 19, 158-162		2
63	Monotherapy with lopinavir/ritonavir versus standard of care in HIV-infected patients virologically suppressed while on treatment with protease inhibitor-based regimens: results from the MoLo study. <i>New Microbiologica</i> , 2014 , 37, 439-48	1.1	2
62	Prevalence and Risk Factors for Significant Liver Fibrosis in Patients with HIV Infection. <i>In Vivo</i> , 2015 , 29, 771-5	2.3	2
61	A Web Based Tool to Enhance Monitoring and Retention in Care for Tuberculosis Affected Patients. <i>Studies in Health Technology and Informatics</i> , 2017 , 237, 204-208	0.5	2
60	Effectiveness, safety, durability and immune recovery in a retrospective, multicentre, observational cohort of ART-experienced, HIV-1-infected patients receiving maraviroc. <i>International Journal of STD and AIDS</i> , 2017 , 28, 1067-1073	1.4	1
59	Cost per care of the first year of direct antiviral agents in the Liguria Region: a multicenter analysis. <i>ClinicoEconomics and Outcomes Research</i> , 2017 , 9, 281-293	1.7	1
58	Immunisation practices in centres caring for children with perinatally acquired HIV: A call for harmonisation. <i>Vaccine</i> , 2016 , 34, 5587-5594	4.1	1
57	Brief Report: Drop in CD4+ Counts Below 200 Cells/µl After Reaching (or Starting From) Values Higher than 350 Cells/µl in HIV-Infected Patients With Virological Suppression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017 , 76, 417-422	3.1	1
56	One-year mortality of HIV-positive patients treated for rifampicin- and isoniazid-susceptible tuberculosis in Eastern Europe, Western Europe, and Latin America. <i>Aids</i> , 2017 , 31, 375-384	3.5	1
55	Trend of eGFR in an Italian cohort of mother-to-child HIV-infected patients exposed to tenofovir for at least 2 years. <i>European Journal of Pediatrics</i> , 2015 , 174, 843-6	4.1	1
54	Relationship between innate immunity, soluble markers and metabolic-clinical parameters in HIV+ patients ART treated with HIV-RNA. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19718	5.4	1
53	Which patients have greatest need for elvitegravir/cobicistat/ emtricitabine/tenofovirDF-based therapy?. <i>Recent Patents on Anti-infective Drug Discovery</i> , 2014 , 9, 41-51	1.6	1
52	Pharmacokinetics of lopinavir determined with an ELISA test in youths with perinatally acquired HIV. <i>Indian Journal of Pediatrics</i> , 2014 , 81, 856-60	3	1
51	Prevalence of etravirine (ETR)-RAMs at NNRTI failure and predictors of resistance to ETR in a large Italian resistance database (ARCA). <i>Clinical Microbiology and Infection</i> , 2013 , 19, E443-6	9.5	1
50	Evaluation of insulin resistance in a cohort of HIV-infected youth. <i>Current Diabetes Reports</i> , 2009 , 9, 260-3	3.6	1

49	Conserved T cell and natural killer cell function in treatment-experienced adults receiving tenofovir plus didanosine as nucleoside reverse transcription inhibitor backbone. <i>Clinical and Experimental Immunology</i> , 2009 , 158, 55-63	6.2	1
48	Nevirapine-based regimens in routine clinical settings: results from a large Italian cohort of HIV-1 infected adults. <i>Current Drug Safety</i> , 2011 , 6, 138-44	1.4	1
47	Simplification to monotherapy with lopinavir/ritonavir in adolescents with vertically acquired HIV-1 infection. <i>Journal of Chemotherapy</i> , 2012 , 24, 56-8	2.3	1
46	Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infection. <i>European Journal of Medical Research</i> , 2009 , 14, 136-8	4.8	1
45	Effects on growth after switching protease inhibitors to efavirenz in HIV-1-infected children. <i>International Journal of Antimicrobial Agents</i> , 2007 , 29, 228-30	14.3	1
44	Persistence of <i>Candida albicans</i> candidemia in non-neutropenic surgical patients: management of a representative patient in the absence of second-line treatment guidelines. <i>Journal of Chemotherapy</i> , 2007 , 19, 335-8	2.3	1
43	Tenofovir use in a patient with a severe renal impairment. <i>HIV Medicine</i> , 2004 , 5, 450-1	2.7	1
42	Ibalizumab and Fostemsavir in the Management of Heavily Pre-Treated HIV-infected Patients. <i>Recent Patents on Anti-infective Drug Discovery</i> , 2018 , 13, 190-197	1.6	1
41	Successful recovery of associated interstitial nephritis and focal segmental glomerulosclerosis in patients with HCV and HIV treated with sofosbuvir and daclatasvir and revision of literature. <i>Clinical Nephrology Case Studies</i> , 2018 , 6, 31-35	1.3	1
40	Delayed diagnosis of tuberculosis in persons living with HIV in Eastern Europe: associated factors and effect on mortality-a multicentre prospective cohort study. <i>BMC Infectious Diseases</i> , 2021 , 21, 1038	4	1
39	Viremia copy-years and risk of estimated glomerular filtration rate reduction in adults living with perinatal HIV infection. <i>PLoS ONE</i> , 2020 , 15, e0240550	3.7	1
38	Switching from tenofovir disoproxil fumarate to tenofovir alafenamide or dual therapy-based regimens in HIV-infected individuals with viral load $\geq 10^5$ copies/mL: does estimated glomerular filtration rate matter?. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106154	14.3	1
37	Risk for Non-AIDS-Defining and AIDS-Defining Cancer of Early Versus Delayed Initiation of Antiretroviral Therapy : A Multinational Prospective Cohort Study. <i>Annals of Internal Medicine</i> , 2021 , 174, 768-776	8	1
36	Onychomadesis in a male patient with secondary syphilis. <i>International Journal of STD and AIDS</i> , 2016 , 27, 704-5	1.4	1
35	The role of hepatitis B vaccine challenge dose in patients with underlying health conditions. <i>Human Vaccines and Immunotherapeutics</i> , 2021 , 17, 575-579	4.4	1
34	Will vaccine hesitancy compromise our efforts to face the next SARS-CoV-2 epidemic wave?. <i>Human Vaccines and Immunotherapeutics</i> , 2021 , 17, 1664-1665	4.4	1
33	Buruli ulcer in a traveller returning from Madagascar: the first report of <i>Mycobacterium ulcerans</i> infection from the region. <i>Journal of Travel Medicine</i> , 2021 , 28,	12.9	1
32	Hypertensive Versus HIV-infected Patients: Who Has the Greatest Target Organ Damage? Comparison of Carotid Plaque Prevalence, Intima Media Thickness and Renal Resistive Index in the Two Groups of Patients. <i>Current Hypertension Reviews</i> , 2018 , 14, 48-55	2.3	1

31	Reversibility of Central Nervous System Adverse Events in Course of Art. <i>Viruses</i> , 2022 , 14, 1028	6.2	1
30	Consecutive blood lactate assessment in HIV-infected children: correlation with therapy and clinical characteristics. <i>International Journal of Infectious Diseases</i> , 2005 , 9, 173-5	10.5	0
29	Migrants and imported disease: Trends of admission in an Italian infectious disease ward during the migration crisis of 2015-2017. <i>BMC Public Health</i> , 2020 , 20, 738	4.1	0
28	Evaluating fostemsavir as a therapeutic option for patients with HIV. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 1539-1545	4	0
27	General Practitioners as partners for a shared management of chronic HIV infection: An insight into the perspectives of Italian People Living with HIV. <i>PLoS ONE</i> , 2021 , 16, e0254404	3.7	0
26	Enhancing care for people living with HIV: current and future monitoring approaches. <i>Expert Review of Anti-Infective Therapy</i> , 2021 , 19, 443-456	5.5	0
25	Missed opportunities in tb clinical practice: How to bend the curve? A medical, social, economic and ethical point of view. <i>Tuberculosis</i> , 2021 , 126, 102041	2.6	0
24	Rationale for an Association Between PD1 Checkpoint Inhibition and Therapeutic Vaccination Against HIV. <i>Frontiers in Immunology</i> , 2018 , 9, 2447	8.4	0
23	Exophytic Lesion of the Tongue in a Patient with Undetectable HIV-RNA in the Past 3 Years. <i>AIDS Research and Human Retroviruses</i> , 2017 , 33, 19-20	1.6	
22	Role of [(18)F]fluorodeoxyglucose positron emission tomography-computed tomography for diagnosis and treatment of sarcoidosis in an HIV-2-infected patient. <i>AIDS Research and Human Retroviruses</i> , 2015 , 31, 868-9	1.6	
21	Commentary: Human Immunodeficiency Virus and Allergic Bronchopulmonary Aspergillosis. <i>Open Forum Infectious Diseases</i> , 2016 , 3, ofw192	1	
20	Modulation of the Natural Killer Cell Compartment during DAAs treatment in Interferon-naïve HCV patients: The type of DAA matters. <i>Immunology Letters</i> , 2018 , 203, 112-115	4.1	
19	Fluoroquinolones in the Treatment of Atypical Mycobacterial Infections in AIDS. <i>Drugs</i> , 1999 , 58, 402-403	2.1	
18	Reuse of Clinical COVID-19 Patient Data: Pre-Processing for Future Classification. <i>Studies in Health Technology and Informatics</i> , 2020 , 275, 117-121	0.5	
17	Off-label use of combined antiretroviral therapy, analysis of data collected by the Italian Register for HIV-1 infection in paediatrics in a large cohort of children.. <i>BMC Infectious Diseases</i> , 2022 , 22, 55	4	
16	The impact of PrEP: results from a multicenter Health Technology Assessment into the Italian setting. <i>Journal of Preventive Medicine and Hygiene</i> , 2020 , 61, E451-E463	1.4	
15	Darunavir-based dual therapy in HIV experienced patients. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19782	5.4	
14	Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort. <i>PLoS ONE</i> , 2016 , 11, e0156360	3.7	

- 13 Marked decrease in acquired resistance to antiretrovirals in latest years in Italy. *Clinical Microbiology and Infection*, **2021**, 27, 1038.e1-1038.e6 9.5
- 12 Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort. *Digestive and Liver Disease*, **2021**, 53, 1603-1609 3.3
- 11 Tuberculosis treatment outcomes in a rural area of Senegal: a decade of experience from 2010 to 2019 by StopTB Italia. *Future Microbiology*, **2021**, 16, 399-407 2.9
- 10 Immunological profile of an infant treated with integrase inhibitor from the neonatal period. *Journal of Virus Eradication*, **2019**, 5, 47-49 2.8
- 9 Response to letter to the editor: switch to dolutegravir and unboosted atazanavir. *Aids*, **2019**, 33, 2263-2264 3.54
- 8 Use of quantitative ultrasound as bone mineral density evaluation in an Italian female population living with HIV: A real-life experience. *Journal of Women and Aging*, **2019**, 31, 176-188 1.4
- 7 Short Communication: Tenofovir Disoproxil Fumarate/Emtricitabine Fits for All as Appropriate HIV-1 Pre-Exposure Prophylaxis?. *AIDS Research and Human Retroviruses*, **2018**, 34, 168-170 1.6
- 6 Hepatitis C virus direct acting antivirals impact on renal function in the first 4 weeks of treatment. *Aids*, **2018**, 32, 1202-1203 3.5
- 5 Comments on "Real-world re-treatment outcomes of direct-acting antiviral therapy failure in patients with chronic hepatitis C". *Journal of Medical Virology*, **2022**, 94, 436-438 19.7
- 4 Tocilizumab and steroid treatment in patients with COVID-19 pneumonia **2020**, 15, e0237831
- 3 Tocilizumab and steroid treatment in patients with COVID-19 pneumonia **2020**, 15, e0237831
- 2 The Ligurian HIV Network: How Medical Informatics Standards Can Help Clinical Research. *Studies in Health Technology and Informatics*, **2019**, 264, 1666-1667 0.5
- 1 Persistence of Unintegrated HIV DNA Associates With Ongoing NK Cell Activation and CD34+DNAM-1brightCXCR4+ Precursor Turnover in Vertically Infected Patients Despite Successful Antiretroviral Treatment.. *Frontiers in Immunology*, **2022**, 13, 847816 8.4